tbuckley/cabot-search huggingface dataset:
AB0231 Higher Peak Disease Activity was Implicated as A Risk Factor in The Development of Vertical Subluxation in RA Patients
Authors: O. Ishida, K. Ikari, A. Taniguchi, H. Yamanaka, S. Momohara
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Instability of the upper cervical spine is common in patients with rheumatoid arthritis (RA) and can lead to sudden death in worst case scenarios. <h3>Objectives</h3> The aim of this study was to evaluate the relationship between upper cervical spine instability and clinical factors, especially focusing on disease activity of RA. <h3>Methods</h3> The study included patients who had been enrolled in the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) cohort study within two years from the onset of RA symptoms and who had cervical spine radiographs taken as part of the preoperative testing for elective joint surgery (e.g. joint replacement surgery) at the institute between April 2010 and March 2013. The anterior atlantodental interval (ADI) and Redlund-Johnell (R-J) values were measured to diagnose atlantoaxial subluxation (AAS) and vertical subluxation (VS), respectively. We obtained clinical data from the IORRA cohort study collecting various clinical data biannually, starting in October 2000. <h3>Results</h3> Finally, the current study included 56 patients. Nearly half of the patients had AAS (27 patients, 48.2%) and 12 patients (21.4%) had VS. In total, 59.6% of the patients had upper cervical instability. There was no significant correlation between the ADI and R-J values (ρ= -0.025; P=0.8). Multiple linear regression analysis revealed the maximum Disease Activity Score in 28 joints (DAS28) during the study period and height were significantly related to R-J values. No variable was significantly associated with the ADI. Univariate logistic regression analyses indicated only the maximum DAS28 during the study period was significantly associated with developing VS, and no variables were shown to be significant in relation to the development of AAS. Median (IQR) values for the maximum DAS28 during the study period in patients with and without VS were 6.1 (5.0 to 6.6) and 5.1 (4.6 to 5.5), respectively. The area under the ROC curve (AUC) showed the predictions using the maximum DAS28 (cutoff = 5.56, specificity = 79.1%, sensitivity = 69.2%, and AUC =0.714) were moderately accurate (Figure 1). <h3>Conclusions</h3> Higher peak disease activity was implicated as a risk factor in the development of VS in RA patients. We suggest that tight control of disease activity is desirable to reduce the risk of VS. <h3>Disclosure of Interest</h3> None declared
Genomic Profiling Combining DNA and RNA Analysis of 112 Formalin-Fixed Paraffin-Embedded Diffuse Large B Cell Lymphoma Specimens Identifies a High Frequency of Clinically Relevant Genomic Alterations
Authors: Andrew M. Intlekofer, Patrick Hilden, Venkatraman E. Seshan, Amanda R. Copeland, Ross L. Levine, Andrew D. Zelenetz, Julie Teruya-Feldstein, Ahmet Dogan, Maria Lia Palomba, Craig H. Moskowitz, Marcel R. M. van den Brink, Kristina M. Knapp, Janine D. Pichardo, Kristina W. Brennan, Geneva Young, Jie He, Michelle K. Nahas, Roman Yelensky, Geoff A. Otto, Doron Lipson, Philip J. Stephens, Vincent A. Miller, Anas Younes
Journal: Blood (2014)
Acute Myeloid Leukemia (AML) - Type Chemotherapy for Newly Diagnosed Children with Myelodysplastic Syndrome (MDS): A Japanese Childhood MDS Study Group Trial MDS99.
Authors: Yoshitoshi Ohtsuka, Atsushi Manabe, Jun Okamura, Seiji Kojima, Akira Ohara, Masahiro Tuchida, Koichiro Ikuta, Shigeyoshi Hibi, Keisei Kawa, Miharu Yabe, Arata Watanabe, Kazuhiro Ueda, Shinpei Nakazawa, Sumio Miyazaki, Tatsutoshi Nakahata
Journal: Blood (2004)
Survival Rates Following Pediatric In-Hospital Cardiac Arrests During Nights and Weekends
Authors: Farhan Bhanji, Alexis A. Topjian, Vinay M. Nadkarni, Amy H. Praestgaard, Elizabeth A. Hunt, Adam Cheng, Peter A. Meaney, Robert A. Berg
Journal: JAMA Pediatrics (2016)

Nearly 6000 hospitalized children in the United States receive cardiopulmonary resuscitation (CPR) annually. Little is known about whether the survival of these children is influenced by the time of the event (eg, nighttime or weekends). Differences in survival could have important implications for hospital staffing, training, and resource allocation.To determine whether outcomes after pediatric in-hospital cardiac arrests differ during nights and weekends compared with days/evenings and weekdays.This study included a total of 354 hospitals participating in the American Heart Association's Get With the Guidelines-Resuscitation registry from January 1, 2000, to December 12, 2012. Index cases (12 404 children) from all children younger than 18 years of age receiving CPR for at least 2 minutes were included. Data analysis was performed in December 2014 and June 2016. We aggregated hourly blocks of time, using previously defined time intervals of day/evening and night, as well as weekend. Multivariable logistic regression models were used to examine the effect of independent variables on survival to hospital discharge. We used a combination of a priori variables based on previous literature (including age, first documented rhythm, location of event in hospital, extracorporeal CPR, and hypotension as the cause of arrest), as well as variables that were identified in bivariate generalized estimating equation models, and maintained significance of P ≤ .15 in the final multivariable models.The primary outcome measure was survival to hospital discharge, and secondary outcomes included return of circulation lasting more than 20 minutes and 24-hour survival.Of 12 404 children (56.0% were male), 8731 (70.4%) experienced a return of circulation lasting more than 20 minutes, 7248 (58.4%) survived for 24 hours, and 4488 (36.2%) survived to hospital discharge. After adjusting for potential confounders, we found that the rate of survival to hospital discharge was lower during nights than during days/evenings (adjusted odds ratio, 0.88 [95% CI, 0.80-0.97]; P = .007) but was not different between weekends and weekdays (adjusted odds ratio, 0.92 [95% CI, 0.84-1.01]; P = .09).The rate of survival to hospital discharge was lower for pediatric CPR events occurring at night than for CPR events occurring during daytime and evening hours, even after adjusting for many potentially confounding patient-, event-, and hospital-related factors.
Love at First Sight
Authors: Michele Y. F. Kong
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
THU0627 Differences in DAS28-CRP and DAS28-ESR Influence Disease Activity Stratification in Rheumatoid Arthritis and Could Influence Use of Biologics, Treatment Efficacy Evaluations and Decisions Regarding Treat-To-Target: An Analysis Using The BSRBR-RA: Table 1.
Authors: P.D.H. Hamann, K. Hyrich, N. McHugh, G. Shaddick, J. Pauling
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Disease activity in rheumatoid arthritis (RA) has traditionally been measured using the 28-joint count disease activity score (DAS28) using ESR. Use of DAS28 using C-reactive protein (CRP) in place of ESR is increasing. This study investigates the level of agreement between the DAS28-ESR and DAS28-CRP scores across different disease activity thresholds and identifies how patient characteristics may influence agreement. <h3>Objectives</h3> To identify the interscore agreement between the DAS28-ESR and DAS28-CRP scores and identify if gender or body mass index (BMI) influence the level of agreement. <h3>Methods</h3> Patients with concurrent measures of ESR and CRP were identified from the BSRBR-RA, enabling paired calculation of DAS28-ESR and DAS28-CRP. Paired scores were stratified by patients9 baseline BMI and gender. Agreement between the scores was compared using Bland-Altman statistics and agreement matrices. <h3>Results</h3> 5457 patients (mean age 56 yrs, 76% female) with 31,084 data entries were identified where paired DAS28-ESR/DAS28-CRP scores could be calculated. Mean DAS28-ESR was 0.3 points (95% CI -0.8 - 1.4) greater than DAS28-CRP (4.4 (SD 1.7) and 4.1 (SD 1.6) respectively). Men had a lower mean difference between the two scores compared with women (DAS28-ESR &gt; DAS28-CRP by 0.2 points (95% CI -1.0 – 1.3) vs. 0.4 points (95% CI -0.7 – 1.4) respectively). The results stratified by BMI were similar to the overall mean difference. Agreement between the two scores according to disease activity thresholds are shown in Table 1. <h3>Conclusions</h3> Overall, the DAS28-ESR classifies fewer patients in remission (15.6% vs. 19.5%) giving a score, on average 0.3 points greater than the DAS28-CRP, with women having a greater difference between the two scores than men. When categorising scores by disease activity thresholds, the DAS28-ESR/DAS28-CRP have lowest agreement at LDA. 54.4% of DAS28-ESR scores were classified as MDA when the paired DAS28-CRP was LDA, which could influence results in clinical trial reporting. Conversely, 20% of patients were classified as being in MDA by DAS28-CRP when the paired DAS28-ESR demonstrated HDA. This is of importance given NICE biologics guidelines, and shows that up to 20% of patients may not satisfy the criteria for biologic therapy if DAS28-CRP were used instead of DAS28-ESR. These results highlight the impact of using the DAS28-ESR or DAS28-CRP interchangeably, and the importance of using a consistent version of the DAS28. <h3>Disclosure of Interest</h3> None declared
Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program
Authors: Raphael Itzykson, Sylvain Thépot, Claire Fabre, Francois Dreyfus, Bruno Quesnel, Eric Wattel, Stephane de Botton, Sylvain Pilorge, Caroline Dartigeas, Aspasia Stamatoullas, Thomas Prebet, Mario Ojeda-Uribe, Stéphane Cheze, Olivier Tournilhac, Eric Solary, Gandhi Damaj, Gerard Tertian, Chantal Himberlin, Rose-Marie Mbida, Blandine Beve, Lionel Adès, Claude Gardin, Pierre Fenaux
Journal: Blood (2008)
OP0233 Genome-Wide Pathway Analysis Reveals that VEGF Genetic Pathway Is Associated with Oral Ulcers in Systemic Lupus Erythematosus
Authors: A. Julià, P. Carreira, R. Blanco, V. Martínez Taboada, L. Carreño Pérez, J. Pérez-Venegas, À. Olivé, J.L. Andreu, M. Aguirre Zamorano, P. Vela, J.M. Nolla, J.L. Marenco de la Fuente, A. Zea, J.M. Pego, M. Freire, E. Díez, A. Aterido, A. Alonso, M. Lόpez-Lasanta, M. Lόpez-Corbeto, R. Tortosa, S. Marsal, A. Fernández-Nebro
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a genetically complex rheumatic disease with heterogeneous clinical manifestations. Recent studies have suggested the existence of a genetic basis for the diverse SLE clinical phenotypes. Also, there is increasing evidence indicating that a substantial part of the genetic variation associated with complex diseases is explained by small-effect genes from common genetic pathways. <h3>Objectives</h3> The objective of the present study was to identify new genetic variation associated with SLE phenotypes using a genome-wide association study at the pathway level. <h3>Methods</h3> A total of 598,258 SNPs were genotyped in a discovery cohort of n=482 SLE patients of southern European ancestry using the Illumina platform Quad610. After quality control analysis, including ancestry estimation using principal-component analysis, genome-wide pathway analysis was performed. A total of 14 clinically relevant SLE phenotypes were tested for association with n&gt;700 reference genetic pathways. Significantly associated pathways (corrected P-value &lt;0.05) were subsequently tested for validation in an independent cohort of n=425 SLE patients from the same ancestry. Both discovery and validation cohort patients were Caucasian European and from Spanish origin, and were recruited by rheumatology departments from n=15 Spanish university hospitals. The validated genetic pathways were functionally characterized using <i>in silico</i> analysis on cell types of relevance in SLE pathogenesis. <h3>Results</h3> In the discovery stage, two genetic pathways were significantly associated with the presence of oral ulcers and antinuclear antibodies in SLE (<i>P</i><sub>FDR</sub>&lt;0.05). In the replication stage, we validated the association between oral ulcers and vascular endothelial growth factor (<i>VEGF</i>) genetic pathway (<i>P</i>=1.3e-2). Analyzing the transcriptional effect of the topical immunotherapies used for the treatment of oral ulcers in SLE, we found a significant differential expression of <i>VEGF</i> pathway genes (<i>P</i>&lt;0.05). <h3>Conclusions</h3> In this work we have performed the first genome-wide association study for clinically relevant SLE phenotype using a pathway-based approach. With this new approach, we have identified and validated the association of VEGF genetic pathway with oral ulcers in SLE. These findings represent an important step towards the characterization of the genetic basis of phenotype heterogeneity in SLE. <h3>Disclosure of Interest</h3> None declared
Interleukin-21-Induced Apoptosis and Cell Death of Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines and Primary Tumors Are Associated with an Induction of Bim.
Authors: Kristopher A. Sarosiek, Jun Chen, Dien G. Pham, Hovav Nechushtan, E. Avisar, Wayne Kindsvogel, Izidore S. Lossos
Journal: Blood (2006)
The Dual E-Selectin/CXCR4 Inhibitor, GMI-1359, Enhances Efficacy of Anti-Leukemia Chemotherapy in FLT3-ITD Mutated Acute Myeloid Leukemia
Authors: Weiguo Zhang, Nalini Patel, William E. Fogler, John L. Magnani, Michael Andreeff
Journal: Blood (2015)
Risk of Hepatitis B Virus (HBV) Reactivation and Role of Anti-Viral Prophylaxis in Lymphoma Patients with Past HBV Infection (HBV Antigen negative but anti-Hepatitis B core antibody positive) Receiving Chemo-Immunotherapy
Authors: Yu Xuan Koo, Shao Weng Tan, Bee Huat Tan, Miriam Tao, Wan Cheng Chow, Soon Thye Lim
Journal: Blood (2008)
THU0419 Rapid3 Performs Well Identifying Treatment Effect in The Tight Control of Psoriatic Arthritis Study
Authors: L.C. Coates, W. Tillett, T. Pincus, A. Kavanaugh, P.S. Helliwell
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> RAPID3 is a patient completed outcome measure assessing disease activity in inflammatory arthritis consisting of the health assessment questionnaire (HAQ) and two VAS scales. It is feasible for use in clinical practice and has been well validated in rheumatoid arthritis (RA) and other conditions, but there is little data on its use in psoriatic arthritis (PsA). <h3>Objectives</h3> To investigate the responsiveness and discrimination of RAPID3 and a modified version with skin VAS in the Tight Control of Psoriatic Arthritis (TICOPA) trial. <h3>Methods</h3> Data from the TICOPA trial were used to assess the performance of the RAPID3 index. RAPID3 was calculated using the HAQ-DI, patient completed pain VAS and global disease activity VAS. Due to concerns about skin involvement in PsA, we also calculated a novel RAPID3Ps score which also included a skin activity VAS to see if performance was superior. Results from the RAPID3 measures were correlated with the PsA disease activity score (PASDAS) a composite disease activity score already validated by GRAPPA. Change in the RAPID3 measures and other outcome measures were compared between the tight control arm and the standard care arm of the TICOPA study using t-test for continuous variables and chi-squared for categorical measures of disease state. <h3>Results</h3> RAPID3 scores strongly correlated with PASDAS (Pearson correlation 0.794, p&lt;0.01) at all baseline and follow up visits. The change in score at follow up was also moderately correlated with the change in PASDAS (0.636, p&lt;0.01). Correlation was similar for the RAPID3Ps at 0.831. When looking at differentiation between treatment groups, change in RAPID3 score at 48 weeks was highly discriminant (t value -3.43, p&lt;0.001) and was higher than all other PsA measures (DAPSA and other individual outcome measures) except for PASDAS (t value -3.75, p&lt;0.001) as shown in the table. Looking at specific cutpoints, RAPID3 "near remission" was also highly discriminant between treatment groups (chi squared 7.48, p=0.006) although with a lower value than the minimal disease activity criteria for PsA (chi squared 10.11, p=0.001). <h3>Conclusions</h3> RAPID3 shows good correlation with other validated measures of disease activity in PsA and addition of a psoriasis measure does not seem necessary in this population. The RAPID3 score and "near remission" definition are able to effectively discriminate between two active treatment groups in an interventional trial. <h3>Acknowledgement</h3> We acknowledge all collaborators and participants in the TICOPA trial. <h3>Disclosure of Interest</h3> None declared
YM477, a Novel Orally-Active Thrombopoietin Receptor Agonist.
Authors: Ken-ichi Suzuki, Masaki Abe, Mari Fukushima-Shintani, Keizo Sugasawa, Fukushi Hirayama, Tomihisa Kawasaki, Hidefumi Hiramatsu, Tatsutoshi Nakahata
Journal: Blood (2005)
Erythropoietin Lacking Hypoxia Responsive Element in 3′ Untranslated Region Stimulates Hepatic Erythropoiesis in Anemic Xenopus.
Authors: Youichi Aizawa, Hironori Nishikawa, Takehito Okui, Nami Nogawa-Kosaka, Nobuyoshi Kosaka, Hiroshi Miyazaki, Takashi Kato
Journal: Blood (2007)
P0359 : ESM-1 is a marker of microvascular invasion, satellite nodules, and adverse clinical outcome in patients with hepatocellular carcinoma treated by surgical resection
Authors: J. Calderaro, J.-C. Nault, P. Bioulac-Sage, M. Tepper, E. Sauce, C. Laurent, C. Costentin, T. Decaens, J.-F. Blanc, D. Azoulay, A. Luciani, A. Laurent, N. Ganne-Carrié, M. Ziol
Journal: Journal of Hepatology (2015)
A Multi-Centre Randomized and Double-Blind Controlled Trial of Rituximab for Warm Autoimune Hemolytic Anemia in Adults
Authors: Marc Michel, Louis Terriou, Françoise Roudot-Thoraval, Mohamed Hamidou, Mikael Ebbo, Guillaume Le guenno, Sylvain Audia, Bruno Royer, anne-Sophie Morin, Jean Marie Michot, Arnaud Jaccard, Laurent Frenzel, Corinne Haioun, Mehdi Khellaf, Bertrand Godeau
Journal: Blood (2015)
Toxicity of Very Prolonged Pegasparaginase and Erwinia Asparaginase Courses in Relation to Asparaginase Activity Levels with a Special Focus on Dyslipidemia
Authors: Wing H. Tong, Rob Pieters, Hester A. de Groot-Kruseman, Wim C.J. Hop, Joachim Boos, Wim J Tissing, Inge M. van der Sluis
Journal: Blood (2014)
FRI0101 Assessment of Large Joint Destruction in Patients with Rheumatoid Arthritis: A Prospective Study Using FDG-PET/CT and Arashi Scoring Method
Authors: T. Suto, Y. Yonemoto, K. Okamura, C. Okura, K. Takagishi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Larsen method has been widely used to assess large joint destruction in patients with rheumatoid arthritis (RA). In that method, various changes might be included within one grade. 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) can visualize the disease activity in large joints affected by RA. <h3>Objectives</h3> The associations between destruction of the large joint and FDG-PET/CT findings were investigated using a new radiographic evaluation method “ARASHI Scoring system”<sup>1</sup>. <h3>Methods</h3> A total of 260 large joints (shoulder, elbow, hip, knee and ankle) in 26 RA patients (six males and 20 females; mean age of 66.9 years) were assessed in this study. FDG-PET/CT was performed at baseline and six months after the initiation of biological therapy. The extent of FDG uptake in large joints was analyzed using the maximum standardized uptake value (SUVmax). Radiographs of the 10 large joints per patient obtained at baseline and after three years were evaluated according to the ARASHI change score. A multiple regression analysis was performed to determine the factors most significantly contributing to the progression of large joint destruction within three years. <h3>Results</h3> Eighteen joints had previously been treated with joint replacement surgery at baseline and nine joints were treated with joint replacement surgery in three years. They were excluded from this study, so we evaluated 233 large joints. The ARASHI status score (score at baseline), SUVmax at baseline, DAS28-ESR and ΔSUV (SUVmax at baseline – SUVmax at six months) were significantly associated with high level changes of ARASHI change score. A multiple regression analysis revealed ΔSUV was found to be the most associated factor with joint destruction at three years (p&lt;0.05). <h3>Conclusions</h3> We investigated large joint destruction in RA patients using FDG-PET/CT and ARASHI scoring method. This study suggested the importance to decrease SUV value in RA patients with high level of SUVmax at baseline for the prevention of large joint destruction. <h3>References</h3> Kaneko A, Matsushita I, Kanbe K, Arai K, Kuga Y, Abe A, Matsumoto T, Nakagawa N, Nishida K. Development and validation of a new radiographic scoring system to evaluate bone and cartilage destruction and healing of large joints with rheumatoid arthritis: ARASHI (Assessment of rheumatoid arthritis by scoring of large joint destruction and healing in radiographic imaging) study. Mod Rheumatol. 2013 Nov;23(6):1053–62. <h3>Disclosure of Interest</h3> None declared